For a patient with type 2 diabetes currently on insulin glargine (Lantus) 16 units daily and a 1‑unit‑per‑6‑gram carbohydrate ratio, how should the insulin dosing be adjusted during transition to palliative care and what key discussion points should be addressed?

Insulin Management for Type 2 Diabetes Transitioning to Palliative Care

For a patient with type 2 diabetes on Lantus 16 units daily transitioning to palliative care, simplify the insulin regimen by continuing basal insulin only at a reduced dose (approximately 12-14 units daily, representing a 10-20% reduction), discontinue the carbohydrate ratio and prandial insulin entirely, and shift the primary goal from tight glycemic control to preventing symptomatic hypoglycemia and severe hyperglycemia (target glucose 200-300 mg/dL). 1, 2, 3

Dose Adjustment Strategy

Immediate Changes to Insulin Regimen

• Reduce basal insulin by 10-20%: Lower the Lantus dose from 16 units to approximately 12-14 units daily to minimize hypoglycemia risk while preventing severe hyperglycemia 1, 3
• Eliminate prandial insulin completely: Discontinue the 1:6 carbohydrate ratio and all rapid-acting insulin, as this complexity is inappropriate for palliative care and increases hypoglycemia risk 1, 2
• Maintain once-daily dosing: Continue administering Lantus at the same time each day for simplicity and consistency 4

Glycemic Target Modification

The American Diabetes Association's 2024 guidelines for palliative care explicitly state different management approaches based on patient status 1, 2, 3:

• For stable palliative patients: Focus on preventing hypoglycemia and managing hyperglycemia to avoid dehydration and osmotic symptoms; there is no role for A1C monitoring 1, 3
• Acceptable glucose range: Allow blood glucose levels between 200-300 mg/dL, which prevents both symptomatic hyperglycemia and hypoglycemia 5
• Avoid tight control: Strict glycemic management is not necessary and may cause harm through increased hypoglycemia risk 2

Monitoring Simplification

• Reduce testing frequency: Decrease blood glucose monitoring to once daily or less, focusing only on symptomatic concerns rather than routine scheduled checks 1, 2
• Discontinue A1C testing: There is no clinical benefit to A1C monitoring in palliative care settings 1, 3
• Monitor for symptoms only: Check glucose when the patient experiences symptoms suggestive of hypoglycemia or severe hyperglycemia (polyuria, dehydration) 1

Key Discussion Points with Patient and Family

Goals of Care Conversation

• Prioritize comfort over control: Explain that the primary goal shifts from preventing long-term complications to maintaining quality of life and preventing acute distressing symptoms 2
• Address HEDIS concerns: Educate that quality indicators for glycemic control do not apply to hospice/palliative patients, and it is medically appropriate to maintain higher glucose levels 5
• Hypoglycemia prevention: Emphasize that preventing low blood sugar is now more important than preventing high blood sugar, as hypoglycemia causes immediate distress while mild-moderate hyperglycemia is generally asymptomatic 1, 3

Medication Simplification Rationale

• Explain the basal-only approach: Oral agents can be used as first-line if appropriate, followed by simplified basal insulin without rapid-acting insulin 1, 2
• Discuss potential discontinuation: As the patient's condition progresses and oral intake decreases, complete discontinuation of all diabetes medications may become appropriate for type 2 diabetes 1, 3
• Avoid agents causing GI distress: Do not use medications that cause nausea or excess weight loss, as these impair quality of life 1, 2

Progressive Adjustment Algorithm

If Patient Remains Stable

• Continue reduced basal insulin (12-14 units daily) 1, 3
• Monitor for signs of dehydration from hyperglycemia (glucose consistently >300 mg/dL) 1
• Adjust dose downward if any hypoglycemia occurs 1, 3

If Organ Failure Develops

• Further reduce insulin dose: Decrease by an additional 20-30% as renal or hepatic function declines 5
• Increase vigilance for hypoglycemia: Dehydration and organ failure increase hypoglycemia risk 1, 3
• Allow higher glucose targets: Permit glucose values in the upper range (250-300 mg/dL) to maximize safety margin 1, 3

If Patient Becomes Actively Dying

• Discontinue all diabetes medications: For type 2 diabetes, stopping all agents including insulin is reasonable when oral intake ceases 1, 3
• Focus entirely on comfort: Treatment and monitoring should stop in the terminal phase 5
• Manage only symptomatic hyperglycemia: Treat only if severe hyperglycemia causes distressing symptoms like dehydration 1

Common Pitfalls to Avoid

• Over-treatment: Continuing aggressive glucose management with prandial insulin and tight targets causes unnecessary hypoglycemia and reduces quality of life 1, 2
• Excessive monitoring: Frequent fingersticks cause discomfort without clinical benefit in palliative care 1, 2
• Ignoring oral intake changes: Insulin doses must be reduced as nutritional intake decreases to prevent hypoglycemia 1, 3
• Provider/family anxiety about hyperglycemia: Mild-moderate hyperglycemia (200-300 mg/dL) is acceptable and preferable to hypoglycemia risk 5

Practical Implementation

Start immediately with:

1. Reduce Lantus from 16 units to 13 units daily 1, 3
2. Stop all rapid-acting insulin and carbohydrate counting 1, 2
3. Reduce glucose monitoring to once daily or as-needed for symptoms 1, 2
4. Set new target range of 200-300 mg/dL 5
5. Educate patient/family on new goals emphasizing comfort and hypoglycemia prevention 2

If hypoglycemia occurs at any point, reduce the basal insulin dose by an additional 10-20% immediately 1, 3. If glucose consistently exceeds 350-400 mg/dL with symptoms of dehydration, consider modest upward adjustment of 1-2 units 1.